BIO
BioXcel Therapeutics, Inc.
Stock
Stock
ISIN: US09075P2048
US09075P2048
Price
Price
CHART BY
Frequently asked questions
What is BioXcel Therapeutics, Inc.'s market capitalization?
The market capitalization of BioXcel Therapeutics, Inc. is $6.61M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$34.43. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BioXcel Therapeutics, Inc.'s stock?
Currently, 4 analysts cover BioXcel Therapeutics, Inc.'s stock, with a consensus target price of $37.00. Analyst ratings provide insights into the stock's expected performance.
What is BioXcel Therapeutics, Inc.'s revenue over the trailing twelve months?
Over the trailing twelve months, BioXcel Therapeutics, Inc. reported a revenue of $2.28M.
What is the EBITDA for BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$72.80M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc. has a free cash flow of -$84.08M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BioXcel Therapeutics, Inc. have, and what sector and industry does it belong to?
BioXcel Therapeutics, Inc. employs approximately 74 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of BioXcel Therapeutics, Inc.'s shares?
The free float of BioXcel Therapeutics, Inc. is 2.58M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $6.61M
- EPS (TTM)
- -$34.43
- Free Float
- 2.58M
- Revenue (TTM)
- $2.28M
- EBITDA (TTM)
- -$72.80M
- Free Cashflow (TTM)
- -$84.08M
Pricing
- 52W span
- $2.11$55.92
Analyst Ratings
The price target is $37.00 and the stock is covered by 4 analysts.
Buy
2
Hold
1
Sell
1
Information
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
- Employees
- 74
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US09075P2048
Knockouts
Finance data from FactSet